Thiotepa (Thioplex)

General information

Class/mechanism: Alkylator, ethylenimine-type, similar to nitrogen mustards. Ethylenimine radicals are released, which alkylates at the N7 position of guanine, resulting in the linkage between the purine and sugar being severed, and subsequent cell damage and death.
Route: IV, intravesicular, intracavitary; (off-label: IT)
Extravasation: irritant or neutral, depending on reference

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.

Diseases for which it is used

• Bladder cancer
• CNS lymphoma
• Peripheral T-cell lymphoma
• Transplant conditioning regimens

Patient drug information

• Patient counseling information can be found in the Thiotepa (Thioplex/Tepadina) package insert
• Thiotepa (Thioplex) patient drug information (Chemocare)
• Thiotepa (Thioplex) patient drug information (UpToDate)

History of changes in FDA indication

• 3/9/1959: Initial FDA approval

Also known as

Tepadina, Thioplex, TESPA, Thiophosphoamide, or TSPA.